Today’s Watch List : SeaDrill Limited (NYSE:SDRL), GreenHunter Resources, Inc. (NYSEMKT:GRH), CTI BioPharma Corp. (NASDAQ:CTIC), Eli Lilly and Company (NYSE:LLY), TSLA

Wells Fargo & Co. reiterated their underperform rating on shares of Seadrill (NASDAQ:SDRL) in a research report released on Wednesday morning. SeaDrill Limited (NYSE:SDRL) shares fell -2.43% in last trading session and ended the day at $24.85. SDRL Gross Margin is 57.90% and its return on assets is 15.90%. SeaDrill Limited (NYSE:SDRL) quarterly performance is -36.51%.

On Sep 16, GreenHunter Resources, Inc. (NYSEMKT:GRH), announced that it has received permits and has completed downhole performance tests on new wells at its Mills Hunter Facility, located in Meigs County, Ohio. Recent bottom hole integrity tests of these wells indicate injection volume capabilities of between 3,000 to 5,000 barrels of oilfield brine water per day per well. This increase in capacity is in line with earlier projections made by the company to double injection capacity by the end of calendar year 2014. The addition of these wells brings GreenHunter’s SWD well count up to 13 in the Appalachian Basin, with a new total daily injection capacity exceeding 31,000 bbls per day. On 02 October, GreenHunter Resources, Inc. (NYSEMKT:GRH) shares fell -2.88% and was closed at $1.35. GRH EPS growth in last 5 year was 44.70%. GreenHunter Resources, Inc. (NYSEMKT:GRH) year to date (YTD) performance is 16.38%.

CTI BioPharma Corp (NASDAQ:CTIC) EVP Matthew Plunkett sold 51,817 shares of the company’s stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $2.58, for a total transaction of $133,687.86. Following the transaction, the executive vice president now directly owns 441,968 shares in the company, valued at approximately $1,140,277. CTI BioPharma Corp. (NASDAQ:CTIC) ended the last trading day at $2.41. Company weekly volatility is calculated as 2.58% and price to cash ratio as 10.88. CTI BioPharma Corp. (NASDAQ:CTIC) showed a weekly performance of -2.82%.

Drugmaker Eli Lilly and Company (NYSE:LLY) on Thursday said it will drop the development of tabalumab, as the results from its two pivotal Phase 3 trials did not meet expectations for efficacy in the context of existing treatments. The decision will result in a pre-tax charge of $75 million or $0.04 to $0.05 per share in the third quarter. Eli Lilly and Company (NYSE:LLY) belongs to Healthcare sector. Its net profit margin is 16.00% and weekly performance is -1.14%. On last trading day company shares ended up $64.83. Eli Lilly and Company (NYSE:LLY) distance from 50-day simple moving average (SMA50) is 2.13%.

Tesla Motors Inc (NASDAQ:TSLA) just sent out invites to a press event on October 9th in Los Angeles, presumably to unveil the new ‘D’ car that founder Elon Musk tweeted about yesterday evening. Now, we officially have an event, to be held at Hawthorne Airport. Tesla Motors Inc (NASDAQ:TSLA) shares increased 4.65% in last trading session and ended the day at $251.42. TSLA Gross Margin is 25.80% and its return on assets is -4.70%. Tesla Motors Inc (NASDAQ:TSLA) quarterly performance is 9.67%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone